zecatrin 4mg modified-release tablets
zentiva pharma uk ltd - fesoterodine fumarate - modified-release tablet - 4mg
zecatrin 8mg modified-release tablets
zentiva pharma uk ltd - fesoterodine fumarate - modified-release tablet - 8mg
teraleve 4mg modified-release tablets
dr reddy's laboratories (uk) ltd - fesoterodine fumarate - modified-release tablet - 4mg
teraleve 8mg modified-release tablets
dr reddy's laboratories (uk) ltd - fesoterodine fumarate - modified-release tablet - 8mg
toviaz tablets 4mg (トビエース錠4mg)
pfizer pharmaceuticals inc. - fesoterodine fumarate - pale blue tablet, major axis: 13 mm, minor axis: 6.5 mm, thickness: 4.8 mm
toviaz tablets 8mg (トビエース錠8mg)
pfizer pharmaceuticals inc. - fesoterodine fumarate - blue tablet, major axis: 13 mm, minor axis: 6.5 mm, thickness: 4.8 mm
tovedeso 3,5 mg tabl. prol.-rel.
teva pharma belgium sa-nv - desfesoterodine succinate 3,5 mg - eq. desfesoterodine 2,6 mg - prolonged-release tablet - 3,5 mg - desfesoterodine succinate 3.5 mg - desfesoterodine
tovedeso 7 mg tabl. prol.-rel.
teva pharma belgium sa-nv - desfesoterodine succinate 7 mg - eq. desfesoterodine 5,2 mg - prolonged-release tablet - 7 mg - desfesoterodine succinate 7 mg - desfesoterodine
detrol la- tolterodine tartrate capsule, extended release
cardinal health - tolterodine tartrate (unii: 5t619tqr3r) (tolterodine - unii:whe7a56u7k) - tolterodine tartrate 2 mg - detrol la capsules is indicated for the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency, and frequency [see clinical studies (14) ]. detrol la is contraindicated in patients with urinary retention, gastric retention, or uncontrolled narrow-angle glaucoma. detrol la is also contraindicated in patients with known hypersensitivity to the drug or its ingredients, or to fesoterodine fumarate extended-release tablets which, like detrol la, are metabolized to 5-hydroxymethyl tolterodine [see warnings and precautions (5.2) (5.3), (5.4) ]. pregnancy category c. at approximately 9–12 times the clinical exposure to the pharmacologically active components of detrol® la, no anomalies or malformations were observed in mice (based on the auc of tolterodine and its 5-hmt metabolite at a dose of 20 mg/kg/day). at 14–18 times the exposure (doses of 30 to 40 mg/kg/day) in mice, tolterodine has been shown to be embryolethal and reduce fetal weight, and increase the incidence of fetal abno
tolterodine tartrate- tolterodine tartrate tablet, film coated
remedyrepack inc. - tolterodine tartrate (unii: 5t619tqr3r) (tolterodine - unii:whe7a56u7k) - tolterodine tablets are indicated for the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency, and frequency. tolterodine tablets are contraindicated in patients with urinary retention, gastric retention, or uncontrolled narrow-angle glaucoma. tolterodine tablets are also contraindicated in patients who have demonstrated hypersensitivity to the drug or its ingredients, or to fesoterodine fumarate extended-release tablets which, like tolterodine tablets, are metabolized to 5-hydroxymethyl tolterodine.